Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Dimethylaminoethanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylaminoethanol SCHEMBL15916955 | 1.00 | — | — | |
| Dimethylaminoethanol SCHEMBL313668 | 0.96 | — | — | |
| Dimethylaminoethanol SCHEMBL27540290 | 0.96 | — | — | |
| Dimethylaminoethanol SCHEMBL67457 | 0.96 | — | — | |
| Dimethylaminoethanol SCHEMBL28154321 | 0.93 | MAPT (0.86) | MAPTALDH1A1TDP1CA12CA2 | |
| Dimethylaminoethanol SCHEMBL22437567 | 0.93 | — | — | |
| Dimethylaminoethanol SCHEMBL22437566 | 0.93 | — | — | |
| Dimethylaminoethanol SCHEMBL13169672 | 0.93 | — | — | |
| Dimethylaminoethanol SCHEMBL2149038 | 0.93 | MAPT (1.00) | MAPTALDH1A1TDP1CA12CA2 | |
| Dimethylaminoethanol SCHEMBL5945 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020065541-A1 | MICROEMULSIONS AND METHODS OF USE | MOROCCANOIL ISRAEL, LTD. (IL) | 2020-04-02 | — | — | WO | claimed |
| CN-104884198-B | The method for preparing the hollow metal nanometer particle being supported on carrier | LG化学株式会社 | 2017-11-17 | — | — | CN | claimed |
| US-20120003319-A9 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2012-01-05 | — | — | US | claimed |
| EP-2271316-A2 | FENOFIBRATE DOSAGE FORMS | Elan Pharma International Limited (IE) | 2011-01-12 | — | — | EP | claimed |
| EP-2268265-A2 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | Elan Pharma International Limited (IE) | 2011-01-05 | — | — | EP | claimed |
| US-7842232-B2 | Sterilization of dispersions of nanoparticulate active agents with gamma radiation | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2010-11-30 | — | — | US | claimed |
| US-20090269400-A1 | Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-10-29 | — | — | US | claimed |
| WO-2009120919-A2 | FENOFIBRATE DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2009-10-01 | — | — | WO | claimed |
| WO-2009117401-A2 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | ELAN PHARAMA INTERNATIONAL LIMITED (IE) | 2009-09-24 | — | — | WO | claimed |
| US-20090238884-A1 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-09-24 | — | — | US | claimed |
| EP-1855651-A1 | NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES | Elan Pharma International Limited (IE) | 2007-11-21 | — | — | EP | claimed |
| WO-2007100466-A2 | NANOPARTICULATE CARVEDILOL FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2007-09-07 | — | — | WO | claimed |
| EP-1809279-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060210638-A1 | Injectable compositions of nanoparticulate immunosuppressive compounds | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-21 | — | — | US | claimed |
| WO-2006096462-A1 | NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-09-14 | — | — | WO | claimed |
| WO-2006052712-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050233001-A1 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL LTD. | 2005-10-20 | — | — | US | claimed |
| US-20050004049-A1 | Novel griseofulvin compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2005-01-06 | — | — | US | claimed |
| US-20040033202-A1 | Nanoparticulate sterol formulations and novel sterol combinations | ELAN PHARMA INTERNATIONAL, LTD. | 2004-02-19 | — | — | US | claimed |
| US-20030224058-A1 | Fibrate particles of an effective average particle size of less than 2000 nm. having a stabilizer associated with the surface; improved pharmacokinetic profiles and reduced fed/fasted variability. | ELAN PHARMA INTERNATIONAL, LTD. | 2003-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210638-A1 | Injectable compositions of nanoparticulate immunosuppressive compounds | RPTOR, IMMT, FKBP4 | CHRM2 4259/4885CHRM3 3914/4885MAPT 1103/4885 |
| US-20090238884-A1 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | ABL1, SI, ABL2 | CHRM2 2748/4885CHRM3 1557/4885MAPT 2929/4885 |
| US-20090269400-A1 | Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin | CLSPN, ABCB11, SLC47A1 | CHRM2 1459/4885CHRM3 2460/4885MAPT 3209/4885 |
| US-20120003319-A9 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE | ABL1, SI, ABL2 | CHRM2 2748/4885CHRM3 1557/4885MAPT 2929/4885 |
| US-20050004049-A1 | Novel griseofulvin compositions | GRN, GRM5, GRM3 | CHRM2 1630/4885CHRM3 1483/4885MAPT 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.